Thromboreductin 0,5 mg Capsules
PDF Leaflet Revision Date: 3 January 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of essential thrombocythaemia to reduce platelet count.
Dosage (summary)
Start with 0.5 mg daily, increase weekly by 0.5 mg; usual maintenance 1.5-3 mg daily.
Onset of Action / Duration
Onset: 2 weeks, Duration: up to 5 mg daily.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Aspirin (increased bleeding risk)
- CYP1A2 inhibitors
- QTc prolonging agents
Contraindications
- Hypersensitivity to anagrelide
- Severe renal insufficiency
- Moderate to severe hepatic insufficiency
- Cardiovascular disease grade 3 or 4
Common side effects
- Headaches
- Palpitations
- Oedema
- Nausea
- Diarrhoea
Counselling Points
- Monitor platelet counts regularly
- Avoid abrupt treatment discontinuation
- Report signs of thrombotic events
Serious warnings
- Risk of thrombotic complications upon treatment discontinuation
- Serious cardiovascular events reported
Important Disclaimer
The Thromboreductin 0,5 mg Capsules professional information leaflet below is the property of Key Oncologics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
